INTERIM ANALYSIS OF A PHASE-III STUDY ON PREOPERATIVE RADIATION-THERAPY IN RESECTABLE RECTAL-CARCINOMA - TRIAL OF THE GASTROINTESTINAL-TRACT CANCER COOPERATIVE GROUP OF THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-ON-TREATMENT-OF-CANCER (EORTC)

被引：0
|
作者：
GERARD, A
BERROD, JL
PENE, F
LOYGUE, J
LAUGIER, A
BRUCKNER, R
CAMELOT, G
ARNAUD, JP
METZGER, U
BUYSE, M
DALESIO, O
DUEZ, N
机构：
[1] HOP ST ANTOINE, F-75571 PARIS 12, FRANCE
[2] HOP TENON, F-75970 PARIS 20, FRANCE
[3] UNIV MAINZ KLINIKEN, MAINZ, FED REP GER
[4] UNIV HOSP BESANCON, BESANCON, FRANCE
[5] CTR MED CHIRURG, STRASBOURG, FRANCE
[6] UNIV HOSP ZURICH, CH-8091 ZURICH, SWITZERLAND
[7] EUROPEAN ORG RES TREATMENT CANC DATA CTR, BRUSSELS, BELGIUM
来源：
CANCER | 1985年 / 55卷 / 10期
关键词：
D O I：
10.1002/1097-0142(19850515)55:10<2373::AID-CNCR2820551012>3.0.CO;2-D
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2373 / 2379
页数：7
相关论文
共 42 条
  • [31] Re: Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: Results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group Phase III Trial (30906)
    Mehraban, D
    Esfahani, F
    JOURNAL OF UROLOGY, 2005, 174 (03): : 1151 - 1151
  • [32] Bacillus Calmette-Guerin versus epirubicin for primary. secondary or concurrent carcinoma in situ of the bladder: Results of a european organization for the research and treatment of Cancer-Genito-urinary Group phase III trial (30906)
    De Reijke, TM
    Kurth, KH
    Sylvester, RJ
    Hall, RR
    Brausi, M
    van de Beek, K
    Landsoght, KEJ
    Carpentier, PC
    JOURNAL OF UROLOGY, 2005, 173 (02): : 405 - 409
  • [33] Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer:: European organization of research and treatment of cancer gastrointestinal group study 40952
    Köhne, CH
    Wils, J
    Lorenz, M
    Schöffski, P
    Voigtmann, R
    Bokemeyer, C
    Lutz, M
    Kleeberg, U
    Ridwelski, K
    Souchon, R
    Ei-Serafi, M
    Weiss, U
    Burkhard, O
    Rückle, H
    Lichinitser, M
    Langenbuch, T
    Scheithauer, W
    Baron, B
    Couvreur, ML
    Schmoll, HJ
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (20) : 3721 - 3728
  • [34] First line infusion of 5-fluorouracil, leucovorin and oxaliplatin for metastatic colorectal cancer :: 4-day chronomodulated (FFI-4-10) versus 2-day FOLFOX2.: A multicenter randomized Phase III trial of the Chronotherapy Group of the European Organization for Research and Treatment of Cancer [EORTC 05963).
    Giacchetti, S
    Bjarnason, G
    Garufi, C
    Tubiana-Mathieu, N
    Iacobelli, S
    Dogliotti, L
    Smaaland, R
    Focan, C
    Coudert, B
    Lévi, F
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 251S - 251S
  • [35] Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) Leukemia Cooperative Groups
    Marysia Hengeveld
    Stefan Suciu
    Matthias Karrasch
    Giorgina Specchia
    Jean-Pierre Marie
    Petra Muus
    Maria C. Petti
    Bruno Rotoli
    Sergio Amadori
    Guiseppe Fioritoni
    Pietro Leoni
    Enrica Morra
    Joseph Thaler
    Luigi Resegotti
    Paola Fazi
    Marco Vignetti
    Franco Mandelli
    Robert Zittoun
    Theo de Witte
    Annals of Hematology, 2012, 91 : 825 - 835
  • [36] Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups
    Hengeveld, Marysia
    Suciu, Stefan
    Karrasch, Matthias
    Specchia, Giorgina
    Marie, Jean-Pierre
    Muus, Petra
    Petti, Maria C.
    Rotoli, Bruno
    Amadori, Sergio
    Fioritoni, Guiseppe
    Leoni, Pietro
    Morra, Enrica
    Thaler, Joseph
    Resegotti, Luigi
    Fazi, Paola
    Vignetti, Marco
    Mandelli, Franco
    Zittoun, Robert
    de Witte, Theo
    ANNALS OF HEMATOLOGY, 2012, 91 (06) : 825 - 835
  • [37] Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: A European organization for research and treatment of cancer genito-urinary group randomized phase III trial
    van der Meijden, APM
    Brausi, M
    Zambon, V
    Kirkels, W
    de Balincourt, C
    Sylvester, R
    JOURNAL OF UROLOGY, 2001, 166 (02): : 476 - 481
  • [38] Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels
    Casali, Paolo G.
    Zalcberg, John
    Le Cesne, Axel
    Reichardt, Peter
    Blay, Jean-Yves
    Lindner, Lars H.
    Judson, Ian R.
    Schoffski, Patrick
    Leyvraz, Serge
    Italiano, Antoine
    Grunwald, Viktor
    Pousa, Antonio Lopez
    Kotasek, Dusan
    Sleijfer, Stefan
    Kerst, Jan M.
    Rutkowski, Piotr
    Fumagalli, Elena
    Hogendoorn, Pancras
    Litiere, Saskia
    Marreaud, Sandrine
    van der Graaf, Winette
    Gronchi, Alessandro
    Verweij, Jaap
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (15) : 1713 - +
  • [39] Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy -: The value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly:: Final report of the Leukemia Cooperative Group of the European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group Randomized Phase III Study AML-9
    Löwenberg, B
    Suciu, S
    Archimbaud, E
    Haak, H
    Stryckmans, P
    de Cataldo, R
    Dekker, AW
    Berneman, ZN
    Thyss, A
    van der Lelie, J
    Sonneveld, P
    Visani, G
    Fillet, G
    Hayat, M
    Hagemeijer, A
    Solbu, G
    Zittoun, R
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (03) : 872 - 881
  • [40] Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): Final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON)
    Lowenberg, B
    Suciu, S
    Archimbaud, E
    Ossenkoppele, G
    Verhoef, GEG
    Vellenga, E
    Wijermans, P
    Berneman, Z
    Dekker, AW
    Stryckmans, P
    Schouten, H
    Jehn, U
    Muus, P
    Sonneveld, P
    Dardenne, M
    Zittoun, R
    BLOOD, 1997, 90 (08) : 2952 - 2961
12345